QQQ   355.08 (+0.87%)
AAPL   180.72 (+0.35%)
MSFT   336.69 (+1.24%)
META   273.15 (+0.20%)
GOOGL   125.07 (+1.09%)
AMZN   124.88 (+1.72%)
TSLA   215.64 (+3.91%)
NVDA   393.07 (-1.16%)
NIO   7.62 (+1.06%)
BABA   84.50 (+1.81%)
AMD   118.20 (-1.06%)
T   15.21 (-3.80%)
F   12.45 (+2.81%)
MU   69.24 (+0.22%)
CGC   0.82 (-1.52%)
GE   106.62 (+1.86%)
DIS   91.11 (+2.84%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.03 (+1.55%)
NFLX   400.33 (-0.69%)
QQQ   355.08 (+0.87%)
AAPL   180.72 (+0.35%)
MSFT   336.69 (+1.24%)
META   273.15 (+0.20%)
GOOGL   125.07 (+1.09%)
AMZN   124.88 (+1.72%)
TSLA   215.64 (+3.91%)
NVDA   393.07 (-1.16%)
NIO   7.62 (+1.06%)
BABA   84.50 (+1.81%)
AMD   118.20 (-1.06%)
T   15.21 (-3.80%)
F   12.45 (+2.81%)
MU   69.24 (+0.22%)
CGC   0.82 (-1.52%)
GE   106.62 (+1.86%)
DIS   91.11 (+2.84%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.03 (+1.55%)
NFLX   400.33 (-0.69%)
QQQ   355.08 (+0.87%)
AAPL   180.72 (+0.35%)
MSFT   336.69 (+1.24%)
META   273.15 (+0.20%)
GOOGL   125.07 (+1.09%)
AMZN   124.88 (+1.72%)
TSLA   215.64 (+3.91%)
NVDA   393.07 (-1.16%)
NIO   7.62 (+1.06%)
BABA   84.50 (+1.81%)
AMD   118.20 (-1.06%)
T   15.21 (-3.80%)
F   12.45 (+2.81%)
MU   69.24 (+0.22%)
CGC   0.82 (-1.52%)
GE   106.62 (+1.86%)
DIS   91.11 (+2.84%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.03 (+1.55%)
NFLX   400.33 (-0.69%)
QQQ   355.08 (+0.87%)
AAPL   180.72 (+0.35%)
MSFT   336.69 (+1.24%)
META   273.15 (+0.20%)
GOOGL   125.07 (+1.09%)
AMZN   124.88 (+1.72%)
TSLA   215.64 (+3.91%)
NVDA   393.07 (-1.16%)
NIO   7.62 (+1.06%)
BABA   84.50 (+1.81%)
AMD   118.20 (-1.06%)
T   15.21 (-3.80%)
F   12.45 (+2.81%)
MU   69.24 (+0.22%)
CGC   0.82 (-1.52%)
GE   106.62 (+1.86%)
DIS   91.11 (+2.84%)
AMC   4.57 (+0.44%)
PFE   38.49 (+1.24%)
PYPL   64.03 (+1.55%)
NFLX   400.33 (-0.69%)
NASDAQ:BIOC

Biocept (BIOC) Stock Forecast, Price & News

$2.11
+0.06 (+2.93%)
(As of 02:55 PM ET)
Compare
Today's Range
$2.02
$2.17
50-Day Range
$2.05
$10.91
52-Week Range
$1.99
$47.70
Volume
41,564 shs
Average Volume
89,270 shs
Market Capitalization
$1.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

Biocept MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
5,481.4% Upside
$120.00 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Biocept in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars


BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

StockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Biocept Announces Pricing Of $5 Mln Underwritten Public Offering
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Biocept shares to commence trading on split-adjusted basis
Biocept Inc BIOC Stock Quote
Biocept (NASDAQ:BIOC) Coverage Initiated at StockNews.com
Biocept (NASDAQ:BIOC) Now Covered by StockNews.com
Biocept Reports 2022 Financial Results
Maxim Group Downgrades Biocept (BIOC)
See More Headlines

BIOC Price History

BIOC Company Calendar

Last Earnings
11/15/2021
Today
6/02/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
104
Year Founded
1993

Price Target and Rating

Average Stock Price Forecast
$120.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+5,481.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,090,000.00
Pretax Margin
-564.02%

Debt

Sales & Book Value

Annual Sales
$25.86 million
Book Value
$4.10 per share

Miscellaneous

Free Float
584,000
Market Cap
$1.27 million
Optionable
Optionable
Beta
0.94

Social Links


Key Executives

  • Samuel D. Riccitelli
    Chairman, President & Chief Executive Officer
  • Philippe Marchand
    Chief Operating Officer
  • Antonino Morales
    Chief Financial Officer, Secretary & Director
  • Nathaniel Sweed
    Medical Director
  • Darrell Taylor
    SVP, Chief Legal & Compliance Officer













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2023?

2 analysts have issued 12 month price objectives for Biocept's stock. Their BIOC share price forecasts range from $120.00 to $120.00. On average, they anticipate the company's share price to reach $120.00 in the next year. This suggests a possible upside of 5,481.4% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2023?

Biocept's stock was trading at $15.90 at the beginning of 2023. Since then, BIOC shares have decreased by 86.5% and is now trading at $2.15.
View the best growth stocks for 2023 here
.

Are investors shorting Biocept?

Biocept saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 7,800 shares, a decline of 24.3% from the April 30th total of 10,300 shares. Based on an average trading volume of 97,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.3% of the shares of the company are short sold.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its earnings results on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 235.66% and a negative net margin of 32.99%. During the same quarter in the prior year, the company earned ($12.90) EPS.

When did Biocept's stock split?

Shares of Biocept reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends
.

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $2.15.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $1.27 million and generates $25.86 million in revenue each year. The medical research company earns $-32,090,000.00 in net income (profit) each year or ($64.2642) on an earnings per share basis.

How many employees does Biocept have?

The company employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -